In, 2019, the FDA and EMA approved Keytruda as first-line treatment in metastatic NSCLC where tumor proportion score (TPS) is greater than 50% (82) and second-line treatment for patients with PD-L1 expression TPS exceeding 1%. This evidence concerns the gene CD274 and non-small cell lung carcinoma.